62 results
424B5
SCTL
Societal CDMO Inc
13 May 21
Prospectus supplement for primary offering
12:00am
believe injectable meloxicam, as a non-opioid product, will overcome many of the issues associated with commonly prescribed opioid therapeutics, including
424B5
SCTL
Societal CDMO Inc
11 May 21
Prospectus supplement for primary offering
5:29pm
tolerated. We believe injectable meloxicam, as a non-opioid product, will overcome many of the issues associated with commonly prescribed opioid
424B5
SCTL
Societal CDMO Inc
26 Feb 21
Prospectus supplement for primary offering
5:30pm
as well as that it has been well tolerated. We believe injectable meloxicam, as a non-opioid product, will overcome many of the issues associated … with commonly prescribed opioid therapeutics, including respiratory depression, excessive nausea and vomiting, constipation, as well having no addiction
424B5
6dwxy
10 Aug 20
Prospectus supplement for primary offering
8:00am
8-K
EX-99.2
2hpg9jws
13 Nov 19
Other Events
7:16am
8-K
EX-99.2
1so9 saskpwdfbb
8 Aug 19
Recro Pharma Reports Second Quarter 2019 Financial Results
7:58am
8-K
EX-99.1
o0gluuy5heoye8mfex7f
20 May 19
Other Events
8:52am
8-K
EX-99.1
4kcue l1v0k6dwqb
10 May 19
Recro Pharma Reports First Quarter 2019 Financial Results
7:05am
8-K
EX-99.1
6y6gcu
5 Apr 19
Cost Associated with Exit or Disposal Activities
4:01pm
8-K
EX-99.1
i8pxisv0lvirsc8f83r3
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.1
6fygsnvtp
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
424B5
tr4 1ek6g51q5nk
19 Feb 19
Prospectus supplement for primary offering
8:39am
8-K
EX-99.2
zxeknqcmd3bjpafgw
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am